Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 5/20 | 0.49 |
| ▸ | ACHE | P22303 | 6/20 | 0.47 |
| ▸ | BCHE | P06276 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | CCR8 | P51685 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1008420 | 0.79 | NR4A2 (0.50) | NR4A2ACHEBCHECHRM1EPHX2 | |
| SCHEMBL7795994 | 0.78 | ACHE (0.67) | NR4A2ACHEBCHECHRM1EPHX2 | |
| SCHEMBL406499 | 0.74 | NR4A2 (0.51) | NR4A2SOS2KMT2AESR1ESR2 | |
| SCHEMBL15281215 | 0.72 | NR4A2 (0.50) | NR4A2ACHEBCHECHRM1EPHX2 | |
| SCHEMBL1062946 | 0.70 | ADORA3 (0.55) | NR4A2ACHEBCHESOS2CCR1 | |
| SCHEMBL11057550 | 0.68 | ACHE (0.67) | ACHEBCHECHRM1KMT2APOLB | |
| SCHEMBL17423119 | 0.67 | POLB (0.55) | NR4A2ACHEBCHECHRM1EPHX2 | |
| SCHEMBL9709249 | 0.67 | MAOA (0.72) | NR4A2ACHECHRM1ESR1ESR2 | |
| SCHEMBL20008613 | 0.67 | NR4A2 (0.53) | NR4A2ACHEBCHECHRM1EPHX2 | |
| SCHEMBL4540441 | 0.67 | APP (0.58) | NR4A2ACHEBCHECHRM1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180263943-A1 | COMPOUND FOR TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 | UNIVERSITAT DE VALÈNCIA, ESTUDI GENERAL (ES) | 2018-09-20 | — | — | US | disclosed |
| EP-3034074-A1 | Compound for treatment of myotonic dystrophy type 1 | Universitat De València, Estudi General (ES) | 2016-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180263943-A1 | COMPOUND FOR TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 | MBNL1, SMN1; SMN2, SQSTM1 | NR4A2 2562/4885ACHE 4376/4885BCHE 4201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.